CAR-T Cell Therapy
Learn how chimeric antigen receptor T-cell technology precisely identifies and eliminates cancer cells
An Immune Cell “Upgrade”
If the human immune system is an army, T cells are its elite special forces. But after prolonged battles with cancer, these “special forces” can become exhausted — or fail to recognize cleverly disguised cancer cells altogether. The idea behind CAR-T is simple: take T cells from the patient, equip them in the laboratory with a “cancer cell navigator” (the chimeric antigen receptor, CAR), expand them in large numbers, and return them to the body. These upgraded T cells can then precisely lock onto and destroy cancer cells carrying the specific target antigen.
Collection
Peripheral blood T cells are collected from the patient through leukapheresis
Engineering
The CAR gene is introduced into T cells to give them targeting ability
Expansion
Cells are expanded in vitro to the numbers needed for treatment
Reinfusion
CAR-T cells are reinfused to precisely attack cancer cells
The Evolution of CAR-T
The concept of CAR-T dates back to 1989, when Israeli scientist Zelig Eshhar first proposed the chimeric antigen receptor. After more than thirty years of basic research and clinical translation, the FDA approved the first CAR-T product, Kymriah, in 2017 — marking CAR-T’s transition from laboratory to clinic. Today more than ten CAR-T products have been approved worldwide, with China and the United States the most active countries in CAR-T clinical research. CAR-T has achieved remarkable efficacy in B-cell hematological malignancies, and scientists are actively exploring its use in solid tumors.
In the Boao Lecheng Pilot Zone, thanks to “special licensed medical” policies, some CAR-T products approved abroad but not yet available in mainland China can be offered to patients. Our expert team provides scientific treatment recommendations based on the latest clinical evidence.
FAQ
How is CAR-T different from ordinary immunotherapy?
Ordinary immunotherapy (such as PD-1 inhibitors) releases the brakes to activate existing T cells. CAR-T directly modifies and strengthens the T cells — like installing a new engine. The two mechanisms are complementary, and clinical studies combining them are underway.
What are the side effects of CAR-T therapy?
The most common side effects include cytokine release syndrome (CRS) and neurotoxicity. After years of clinical practice, physicians have mature management protocols for both. Every CAR-T patient is closely monitored by a professional medical team.
Want to know if CAR-T therapy suits your situation?
📞 +86-898-36860235Related Articles
该分类下暂无文章